DAINIPPON SUMITOMO - Latuda On Track! Approaching Milestones Will Continue To Drive Growth!
Dainippon Sumitomo’s sole growth driver, Latuda sales is ramping up well and it is better than recently launched Saphris and Fanapt. Our analysis suggests that Latuda will be successful in fetching more Rx share in the US and Clinical data in Schizophrenia and Bipolar disorder are expected to come positive and drive growth. Street perceives Latuda as just another atypical anti-psychotic in the ~$15.8b anti-psychotics market, which will be largely genericized soon. However, high unmet need exists due to a large no. of patients not responding to any therapy, this along with associated side-effects with every drug, push psychiatrists in switching therapy in regular intervals.
This report analyzes various data points viz physicians survey, clinical data, Rx share and SWOT analysis and concludes that Latuda will be successful in anti-psychotic market.
This report analyzes various data points viz physicians survey, clinical data, Rx share and SWOT analysis and concludes that Latuda will be successful in anti-psychotic market.
COMPANIES MENTIONED
Dainippon Sumitomo
Dainippon Sumitomo
